We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
To selectivity and beyond.
- Authors
Mack, George S.
- Abstract
The article focuses on the efforts of drug developers to produce a second generation of agents that target the newly recognized enzymes involved in DNA and chromatin modification. It is hoped that the newer inhibitors will not only have an improved therapeutic index but also open up an epigenetic therapy to indications outside of cancer. Information is provided on a number of histone deacetylase (HDAC) inhibitor programs that are in the stage of development, including mocetinostat from MethylGene which is in phase 2 trials for follicular lymphoma.
- Subjects
DRUG development; ENZYME inhibitors; CHROMATIN; CANCER treatment; HISTONE deacetylase
- Publication
Nature Biotechnology, 2010, Vol 28, Issue 12, p1259
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt.1724